Cardlytics’ (CDLX) Neutral Rating Reiterated at Bank of America

Bank of America restated their neutral rating on shares of Cardlytics (NASDAQ:CDLXFree Report) in a research report sent to investors on Thursday, Marketbeat.com reports. They currently have a $11.00 target price on the stock.

Other research analysts have also recently issued reports about the company. Needham & Company LLC reaffirmed a buy rating and set a $12.00 price objective on shares of Cardlytics in a research report on Tuesday, June 11th. Northland Capmk raised Cardlytics to a strong-buy rating in a research report on Tuesday, June 18th. Northland Securities started coverage on Cardlytics in a report on Tuesday, June 18th. They issued an outperform rating and a $14.00 target price for the company. Lake Street Capital boosted their target price on Cardlytics from $13.00 to $18.00 and gave the company a buy rating in a report on Friday, March 15th. Finally, Craig Hallum reduced their target price on Cardlytics from $18.00 to $12.00 and set a buy rating for the company in a report on Thursday, May 9th. Two equities research analysts have rated the stock with a hold rating, four have given a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat, Cardlytics currently has an average rating of Moderate Buy and a consensus price target of $12.67.

Read Our Latest Report on Cardlytics

Cardlytics Trading Down 0.9 %

CDLX opened at $8.04 on Thursday. Cardlytics has a 12 month low of $5.53 and a 12 month high of $20.52. The stock has a market capitalization of $392.19 million, a price-to-earnings ratio of -1.82 and a beta of 1.67. The company has a debt-to-equity ratio of 1.30, a current ratio of 2.13 and a quick ratio of 2.13. The business has a fifty day moving average price of $10.41 and a 200 day moving average price of $9.57.

Cardlytics (NASDAQ:CDLXGet Free Report) last released its quarterly earnings data on Wednesday, May 8th. The company reported ($0.35) earnings per share (EPS) for the quarter. The business had revenue of $67.61 million for the quarter. Cardlytics had a negative return on equity of 25.36% and a negative net margin of 55.23%.

Insider Buying and Selling at Cardlytics

In related news, major shareholder Clifford Sosin acquired 225,000 shares of Cardlytics stock in a transaction on Thursday, May 9th. The stock was purchased at an average cost of $8.73 per share, with a total value of $1,964,250.00. Following the purchase, the insider now directly owns 6,361,113 shares in the company, valued at $55,532,516.49. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. In other Cardlytics news, major shareholder Clifford Sosin bought 225,000 shares of the company’s stock in a transaction on Thursday, May 9th. The shares were bought at an average price of $8.73 per share, for a total transaction of $1,964,250.00. Following the transaction, the insider now owns 6,361,113 shares of the company’s stock, valued at approximately $55,532,516.49. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, CEO Karim Saad Temsamani sold 43,129 shares of the business’s stock in a transaction that occurred on Tuesday, June 4th. The stock was sold at an average price of $8.65, for a total value of $373,065.85. Following the transaction, the chief executive officer now owns 385,530 shares in the company, valued at approximately $3,334,834.50. The disclosure for this sale can be found here. Insiders sold a total of 79,435 shares of company stock valued at $828,269 in the last ninety days. Insiders own 4.40% of the company’s stock.

Institutional Investors Weigh In On Cardlytics

Institutional investors and hedge funds have recently modified their holdings of the company. Tower Research Capital LLC TRC grew its holdings in Cardlytics by 349.3% during the 4th quarter. Tower Research Capital LLC TRC now owns 9,602 shares of the company’s stock valued at $88,000 after buying an additional 7,465 shares during the last quarter. SG Americas Securities LLC grew its holdings in Cardlytics by 34.3% during the 4th quarter. SG Americas Securities LLC now owns 21,461 shares of the company’s stock valued at $198,000 after buying an additional 5,484 shares during the last quarter. Clear Street Markets LLC acquired a new stake in Cardlytics during the 4th quarter valued at $199,000. Banco Santander S.A. acquired a new stake in Cardlytics during the 1st quarter valued at $199,000. Finally, Check Capital Management Inc. CA grew its holdings in Cardlytics by 14.0% during the 4th quarter. Check Capital Management Inc. CA now owns 23,200 shares of the company’s stock valued at $214,000 after buying an additional 2,850 shares during the last quarter. Institutional investors and hedge funds own 68.10% of the company’s stock.

About Cardlytics

(Get Free Report)

Cardlytics, Inc operates an advertising platform in the United States and the United Kingdom. It offers Cardlytics platform, a proprietary native bank advertising channel that enables marketers to reach customers through their network of financial institution partners through digital channels, such as online, mobile applications, email, and various real-time notifications; and Bridg platform, a customer data platform which utilizes point-of-sale data and enables marketers to perform analytics and targeted loyalty marketing, as well as measure the impact of their marketing.

Featured Articles

Analyst Recommendations for Cardlytics (NASDAQ:CDLX)

Receive News & Ratings for Cardlytics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cardlytics and related companies with MarketBeat.com's FREE daily email newsletter.